Eldepryl: profile and news

Peer At Every Study For Signs Of Calorie Restriction Sep 6, 2005
...time as a research fellow in neurodegenerative disease: almost all medication tried in mice increased their lifespan: levodopa, pergolide, eldepryl, you name it ... - Methuselah Foundation,

Michael J. Fox and Parkinson's Disease Aug 28, 2005
...with medication that can be made into dopamine in the brain (Sinemet), or by drugs that seem to affect the use of dopamine in the brain (Symmetrel, Eldepryl). ... - rarediseases.about.com <**results**>

Michael J. Fox and Parkinson's Disease Jun 27, 2005
...with medication that can be made into dopamine in the brain (Sinemet), or by drugs that seem to affect the use of dopamine in the brain (Symmetrel, Eldepryl). ... - rarediseases.about.com

Michael J. Fox and Parkinson's Disease 13 Sep 2002
...with medication that can be made into dopamine in the brain (Sinemet), or by drugs that seem to affect the use of dopamine in the brain (Symmetrel, Eldepryl). ... - rarediseases.about.com

Michael J. Fox and Parkinson's Disease Apr 4, 2005
...with medication that can be made into dopamine in the brain (Sinemet), or by drugs that seem to affect the use of dopamine in the brain (Symmetrel, Eldepryl). ... - rarediseases.about.com

Webster v. NFL: A family's fight Mar 12, 2005
Percocet, Ultram, Vicodin (pain killers), Lasix, magnesium, potassium (for kidney and blood levels), Dicloxacillin (antibiotic), Eldepryl (for Parkinson's ... - Pittsburgh Post Gazette,

Michael J. Fox and Parkinson's Disease Feb 14, 2005
...with medication that can be made into dopamine in the brain (Sinemet), or by drugs that seem to affect the use of dopamine in the brain (Symmetrel, Eldepryl). ... - rarediseases.about.com

Other information

Indication
For the adjunct treatment for Parkinson's Disease

Pharmacology
Dopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.

Mechanism Of Action
Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the inhibition of monoamine oxidase type B (MAO B) is thought to be of primary importance. MAO B is involved in the oxidative deamination of dopamine in the brain. Selegiline is best known as an irreversible inhibitor of MAO. MAO's activity is inhibited when selegiline binds to the isoalloxazine flavin adenine dinucleotide (FAD) at its active center. In addition, there is evidence that selegiline may increase dopaminergic activity through other mechanisms.

Drug Category
Dopaminergics; Neuroprotective Agents; Antiparkinson Agents; Antidyskinetics; Central Nervous System Agents; ATC:N04BD01

Brand Names/Synonyms
Apo-Selegiline; Carbex; Eldepryl; Gen-Selegiline; Jumex; L-Deprenalin; L-E 250; Novo-Selegiline; Nu-Selegiline; Sd Deprenyl; Selegeline Hcl; Selegilina [Inn-Spanish]; Selegiline; Selegiline Hcl; Selegiline-5; Selegilinum [Inn-Latin]

Dosage Forms
TABLET

Absorption
Rapidly absorbed from the gastrointestinal tract

Interactions
Interactions for Selegiline:

The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination. Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).

-->

Chemical IUPAC Name
N-methyl-N-(1-methyl-2-phenyl-ethyl)-prop-2-yn-1-amine

Chemical Formula
C13H17N

Half Life
2 hours

Drug Type
Approved Drug

# Accession No
APRD00525

CAS Registry Number
14611-51-9